Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment
October 31 2023 - 12:59PM
Dow Jones News
By Chris Wack
Mersana Therapeutics shares were up 8% to $1.20 after the
company said the U.S. Food and Drug Administration has lifted the
clinical hold on its Phase 1 trial of XMT-2056.
The stock is down 84% in the past 12 months.
XMT-2056 is a systemically administered Immunosynthen
antibody-drug conjugate that is designed to target a novel human
epidermal growth factor receptor 2 epitope and locally activate
signaling in both tumor-resident immune cells and in tumor
cells.
The Phase 1 open-label trial is investigating XMT-2056 in
previously treated patients with advanced/recurrent solid tumors
expressing HER2, including breast, gastric, colorectal and
non-small-cell lung cancers. The dose escalation and dose expansion
portions of the trial will evaluate and characterize the
relationship of safety, tolerability and exposure of XMT-2056.
The FDA has granted orphan drug designation to XMT-2056 for the
treatment of gastric cancer. In August 2022, Mersana entered into a
global collaboration providing GSK with an exclusive option to
co-develop and commercialize XMT-2056. GSK has not yet exercised
this option.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 31, 2023 12:44 ET (16:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024